Higher drug resistance resulting from the activation of the JAK/STAT3 pathway has been reported in various human CSCs38–40; thus, we investigated whether this aberrant signaling could also confer drug resistance in human CRC cells. Here, STAT3 is linked to colorectal carcinoma.